Paper65452
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
Gonsette RE and 2 others. J Neurol, 1977. Cited by 100 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Download JSON
Cite this record
ConductScience Library. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years. Papers, record 65452. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/65452
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cyclophosphamide | Major topic |
| Multiple Sclerosis | Major topic |
| Adult | |
| Follow-Up Studies | |
| Humans |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 72,790 | Failure of basic protein therapy for multiple sclerosis. | J Neurol | 1977 | https://conductscience.org/library/papers/72790 | PubMed |
| 2 | 4,119,511 | Multiple sclerosis unaffected by azathioprine in pilot study. | Arch Neurol | 1973 | https://conductscience.org/library/papers/4119511 | PubMed |
| 3 | 5,035,906 | Effect of 'maximum immune suppression' with thoracic duct drainage, ALG, azathioprine and cortisone in some neurological disorders. | Proc R Soc Med | 1972 | https://conductscience.org/library/papers/5035906 | PubMed |
| 4 | 1,237,376 | Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response. | Clin Exp Immunol | 1975 | https://conductscience.org/library/papers/1237376 | PubMed |
| 5 | 5,783,817 | A preliminary evaluation of azathioprine (Imuran) in the treatment of multiple sclerosis. | Henry Ford Hosp Med J | 1969 | https://conductscience.org/library/papers/5783817 | PubMed |
| 6 | 4,563,026 | Immune status of patients with multiple sclerosis. Analysis of primary and established immune responses in 24 patients. | Neurology | 1972 | https://conductscience.org/library/papers/4563026 | PubMed |
| 7 | 6,025,851 | [Immunodepressive therapy in neurology]. | Presse Med (1893) | 1967 | https://conductscience.org/library/papers/6025851 | PubMed |
| 8 | 4,358,999 | Evaluation of antithymocyte globulin in acute relapses of multiple sclerosis. | Neurology | 1974 | https://conductscience.org/library/papers/4358999 | PubMed |
| 9 | 5,710,171 | [Immunosuppressive agents in multiple sclerosis. Preliminary trials with Proresid]. | Wien Med Wochenschr | 1968 | https://conductscience.org/library/papers/5710171 | PubMed |
| 10 | 4,367,744 | [Critic study of multiple sclerosis treatment by chlorambucil and intraspinal corticotherapy. Apropos of 100 cases followed up from 2 to 9 years]. | Rev Neurol (Paris) | 1973 | https://conductscience.org/library/papers/4367744 | PubMed |
| 11 | 4,180,869 | Cyclophosphamide in multiple sclerosis. | Lancet | 1969 | https://conductscience.org/library/papers/4180869 | PubMed |
| 12 | 4,541,183 | Failure of antilymphocytic globulin therapy in chronic progressive multiple sclerosis. | Neurology | 1973 | https://conductscience.org/library/papers/4541183 | PubMed |
| 13 | 4,139,403 | Intensive immunosuppression in the treatment of multiple sclerosis. | Lancet | 1974 | https://conductscience.org/library/papers/4139403 | PubMed |
| 14 | 1,097,604 | Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies. | J Neurol Neurosurg Psychiatry | 1975 | https://conductscience.org/library/papers/1097604 | PubMed |
| 15 | 5,906,182 | [Multiple sclerosis and the autoimmunization process. Treatment by antimitotics]. | Lyon Med | 1966 | https://conductscience.org/library/papers/5906182 | PubMed |
| 16 | 171,349 | An immunopathologic component in experimental togavirus encephalitis. | J Neuropathol Exp Neurol | 1975 | https://conductscience.org/library/papers/171349 | PubMed |
| 17 | 765,862 | [Treatment of multiple sclerosis using immunosuppression. Critical discussion of results]. | Ned Tijdschr Geneeskd | 1976 | https://conductscience.org/library/papers/765862 | PubMed |
| 18 | 5,516,334 | [Treatment of multiple sclerosis with intraspinal antilymphocyte serum: theoretical bases; opportunities for utilization]. | Rev Neurol (Paris) | 1970 | https://conductscience.org/library/papers/5516334 | PubMed |
| 19 | 4,631,348 | Therapeutic trial of immunosuppressive agents in multiple sclerosis. | Neurology | 1972 | https://conductscience.org/library/papers/4631348 | PubMed |
| 20 | 4,314,087 | Multiple sclerosis: pilot therapeutic trial of immunosuppressants. | Schweiz Arch Neurol Neurochir Psychiatr | 1969 | https://conductscience.org/library/papers/4314087 | PubMed |
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 100 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 34,940,954 | Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. | CNS Drugs | 2022 | https://conductscience.org/library/papers/34940954 | PubMed |
| 34,079,516 | Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities. | Front Neurol | 2021 | https://conductscience.org/library/papers/34079516 | PubMed |
| 27,928,949 | From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis. | Curr Neuropharmacol | 2017 | https://conductscience.org/library/papers/27928949 | PubMed |
| 23,271,506 | Role of immunosuppressive therapy for the treatment of multiple sclerosis. | Neurotherapeutics | 2013 | https://conductscience.org/library/papers/23271506 | PubMed |
| 21,865,410 | Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. | Mult Scler | 2012 | https://conductscience.org/library/papers/21865410 | PubMed |
| 21,547,093 | Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. | Autoimmune Dis | 2011 | https://conductscience.org/library/papers/21547093 | PubMed |
| 19,774,497 | Immunomodulatory therapies in neurologic critical care. | Neurocrit Care | 2010 | https://conductscience.org/library/papers/19774497 | PubMed |
| 19,439,723 | Cyclophosphamide therapy in pediatric multiple sclerosis. | Neurology | 2009 | https://conductscience.org/library/papers/19439723 | PubMed |
| 17,253,481 | Cyclophosphamide for multiple sclerosis. | Cochrane Database Syst Rev | 2007 | https://conductscience.org/library/papers/17253481 | PubMed |
| 15,940,386 | The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up. | J Neurol | 2005 | https://conductscience.org/library/papers/15940386 | PubMed |
| 15,645,351 | Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. | J Neurol | 2004 | https://conductscience.org/library/papers/15645351 | PubMed |
| 6,896,866 | Intrathecal methylprednisolone acetate in multiple sclerosis treatment: effect on the blood-CSF barrier and on the intrathecal IgG production. | Ital J Neurol Sci | 1982 | https://conductscience.org/library/papers/6896866 | PubMed |
| 6,196,462 | Immunological treatment of multiple sclerosis. | J Neurol | 1983 | https://conductscience.org/library/papers/6196462 | PubMed |
| 6,164,763 | Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study. | J Neurol | 1981 | https://conductscience.org/library/papers/6164763 | PubMed |
| 6,157,007 | Azathioprine in multiple sclerosis--a 3 year controlled study of its effectiveness. | J Neurol | 1980 | https://conductscience.org/library/papers/6157007 | PubMed |
| 3,571,433 | Increased spontaneous immunoglobulin secretion associated with cyclophosphamide-induced immune suppression. | J Clin Immunol | 1987 | https://conductscience.org/library/papers/3571433 | PubMed |
| 3,429,217 | Short-term intensive cyclophosphamide treatment in progressive multiple sclerosis. | Ital J Neurol Sci | 1987 | https://conductscience.org/library/papers/3429217 | PubMed |
| 3,171,613 | The need for a new strategy for the treatment of multiple sclerosis. | J Neurol | 1988 | https://conductscience.org/library/papers/3171613 | PubMed |
| 2,982,564 | Multiple sclerosis. Current concepts in management. | Drugs | 1985 | https://conductscience.org/library/papers/2982564 | PubMed |
| 2,850,189 | T-lymphocyte subpopulations in multiple sclerosis--do they help to judge immunosuppressive therapy? | Eur Arch Psychiatry Neurol Sci | 1988 | https://conductscience.org/library/papers/2850189 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/65452
GET https://conductscience.org/api/papers/v1/65452/references?page=2